Table 2.

Pathways and markers tested. Positivity of one pathway marker was sufficient to score for positivity of the respective pathway. H‐Score of 100 was used for positive interpretation of all markers except p53, where ≥10% positive cells were considered positive.

Pathway	Patients tested		Patients not tested		Patients positive		Patients negative		Patients unspecific
Marker	n	(% of all patients)	n	(% of all patients)	n	(% of patients tested)	n	(% of patients tested)	n	(% of patients tested)
HDAC	59	96,7	2	3,3	49	83,1	9	15,3
HDAC2	59	96,7	2	3,3	49	83,1	9	15,3	1	1,7
HR23B	50	82,0	11	18,0	44	88,0	2	4,0	4	8,0
EGF	47	77,0	14	23,0	41	87,2	5	10,6
p‐EGFR	47	77,0	14	23,0	41	87,2	5	10,6	1	2,1
PDGF	54	88,5	7	11,5	41	75,9	13	24,1
PDGFR alpha	54	88,5	7	11,5	5	9,3	49	90,7	0	0,0
PDGFR beta	54	88,5	7	11,5	39	72,2	14	25,9	1	1,9
MAPK	60	98,4	1	1,6	26	43,3	34	56,7
p‐ERK	60	98,4	1	1,6	24	40,0	36	60,0	0	0,0
BRAF V600E	13	21,3	48	78,7	2	15,4	11	84,6	0	0,0
p53	52	85,2	9	14,8	26	50,0	26	50,0
p53	52	85,2	9	14,8	26	50,0	26	50,0	0	0,0
PI3K/m‐TOR	61	100,0	0	0,0	21	34,4	39	63,9
p‐AKT	60	98,4	1	1,6	8	13,3	51	85,0	1	1,7
p‐S6	19	31,1	42	68,9	19	100,0	0	0,0	0	0,0